- Home
- TLPH
TLPH
Talphera Inc.
as 12-24-2024 4:00pm EST
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 12.7M | IPO Year: | 2011 |
| Target Price: | $4.50 | AVG Volume (30 days): | 89.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.60 - $1.61 | Next Earning Date: | 11-13-2024 |
| Revenue: | $281,000 | Revenue Growth: | -24.05% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Talphera Inc. (TLPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | TLPH | CHIEF EXECUTIVE OFFICER | Dec 5 '24 | Buy | $0.64 | 5,000 | $3,199.50 | 208,066 | |
| ASADORIAN RAFFI | TLPH | Chief Financial Officer | Dec 2 '24 | Sell | $0.77 | 155 | $118.89 | 37,578 | |
| Angotti Vincent J. | TLPH | CHIEF EXECUTIVE OFFICER | Nov 27 '24 | Buy | $0.73 | 5,000 | $3,649.50 | 208,066 |
Latest Talphera Inc. News
TLPH Breaking Stock News: Dive into TLPH Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Simply Wall St.
a month ago
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)
GuruFocus.com
a month ago
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
PR Newswire
a month ago
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
2 months ago
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
PR Newswire
3 months ago
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
PR Newswire
4 months ago
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR Newswire
4 months ago
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Compare TLPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TLPH Talphera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.